XOMANASDAQ: XOMA

XOMA Royalty has acquired 50 percent of Twist's existing royalty and milestone economics for $15 million XOMA Royalty's portfolio now holds over 100 assets ranging from revenue-generating commercial therapeutics to pre-clinical programs EMERYVILLE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) announced today it has entered into a $15 million royalty monetization arrangement with Twist Bioscience Corporation to acquire a 50 percent economic interest in all future milestones and royalties associated with the 60-plus partnered early-stage programs across 30 partners enabled by Twist Bioscience's Biopharma Solutions business unit.

XOMA Royalty Corporation offers diversified revenue streams from milestone and royalty rights in various therapeutic areas, providing stable returns with lower clinical trial risks. The company's preferred shares, XOMAP and XOMAO, offer high, reliable dividends, making them attractive for income investors seeking biotech exposure. XOMA's robust financials, including substantial cash reserves and non-dilutive financing, ensure the sustainability of dividend payments for many years.

XOMA (XOMA, Financial), a company engaged in biotechnology royalties, saw its stock price plummet by 5.36%, with the latest price reported at $25.91. The trading volume reached 3,638 shares, representing a turnover rate of 0.03% and a price fluctuation amplitude of 3.79%.

EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share.

EMERYVILLE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following September 2024 investor conferences:

Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from  Day One Pharmaceuticals and Rezolute

Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

XOMA Corporation operates as a biotechnology royalty aggregator, acquiring economic rights to milestones and royalties from approved or clinical-stage drugs. XOMA's diverse IP portfolio spans various therapeutic areas, including oncology, immunology, rare diseases, and acute pain, mitigating investment risks. The recent acquisition of Kinnate Biopharma extends XOMA's portfolio into oncology despite Kinnate selling its crown jewel, exarafenib, before the acquisition.

EMERYVILLE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share.